Scientists discover that two thirds of the malaria parasite's genes are essential for normal growth, meaning there are many more possible drug targets than previously thought.
Two studies recently published in The Lancet Infectious Diseases identified genic markers of Plasmodium falciparumthat are associated with resistance to the antimalarial drug piperaquine.
Melbourne researchers are part of an international collaboration that has performed the first large-scale genomic analysis of P. vivax malaria infections.